Medicare May Pay for Ornish, Pritikin Programs

The Centers for Medicare and Medicaid Services said it was considering Medicare payment for the diet and exercise programs developed by Dean Ornish, MD, and Nathan Pritikin for reversing coronary heart disease.

Stocking Up on Meds Saves Money (CME/CE, with video)

Buying prescription drugs in bulk reduces costs for both patients and their insurers, researchers say.

House Passes Medicare Payment Fix

WASHINGTON (MedPage Today) — By a vote of 243 to 183, the House of Representatives has passed a bill to fix the flawed Medicare physician payment formula, but the measure faces a fight in the Senate.

FDA Issues Warning for Defective AEDs

WASHINGTON (MedPage Today) — The FDA is warning of potential malfunctions in some 300,000 defibrillators manufactured by Cardiac Science Corporation which may prevent the devices from delivering lifesaving shocks but don’t show up on device self-tests.

FDA Warns of Bacteria in Nasal Spray

WASHINGTON (MedPage Today) — Several lots of Vicks Sinex nasal spray have been recalled because of bacteria found in the solution during a quality control inspection, the FDA announced.

Stocking Up on Meds Saves Money (CME/CE, with video)

Buying prescription drugs in bulk reduces costs for both patients and their insurers, researchers say.

POZEN commences enrollment in PA32540 phase 3 study

POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

EMEA’s CHMP recommends approval of Merck’s ELONVA

Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted [...]

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.